325 related articles for article (PubMed ID: 33549390)
1. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.
Pinpathomrat N; Bull N; Pasricha J; Harrington-Kandt R; McShane H; Stylianou E
Vaccine; 2021 Mar; 39(9):1452-1462. PubMed ID: 33549390
[TBL] [Abstract][Full Text] [Related]
2. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
Khanna M; Rady H; Dai G; Ramsay AJ
Vaccine; 2021 Mar; 39(12):1780-1787. PubMed ID: 33632562
[TBL] [Abstract][Full Text] [Related]
3. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
[TBL] [Abstract][Full Text] [Related]
4. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
6. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
7. Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice.
Hu Z; Wong KW; Zhao HM; Wen HL; Ji P; Ma H; Wu K; Lu SH; Li F; Li ZM; Shu T; Xu JQ; Lowrie DB; Fan XY
Mol Ther; 2017 May; 25(5):1222-1233. PubMed ID: 28342639
[TBL] [Abstract][Full Text] [Related]
8. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
Zhang M; Dong C; Xiong S
Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
[TBL] [Abstract][Full Text] [Related]
9. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A.
Stylianou E; Griffiths KL; Poyntz HC; Harrington-Kandt R; Dicks MD; Stockdale L; Betts G; McShane H
Vaccine; 2015 Nov; 33(48):6800-8. PubMed ID: 26478198
[TBL] [Abstract][Full Text] [Related]
10. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
[TBL] [Abstract][Full Text] [Related]
11. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
[TBL] [Abstract][Full Text] [Related]
13. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15.
Jia Q; Masleša-Galić S; Nava S; Horwitz MA
mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
[TBL] [Abstract][Full Text] [Related]
16. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
17. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.
Xu Y; Yang E; Wang J; Li R; Li G; Liu G; Song N; Huang Q; Kong C; Wang H
Immunology; 2014 Oct; 143(2):277-86. PubMed ID: 24773322
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
20. IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations.
Morelli MP; Del Medico Zajac MP; Pellegrini JM; Amiano NO; Tateosian NL; Calamante G; Gherardi MM; García VE
Front Cell Infect Microbiol; 2020; 10():581812. PubMed ID: 33072631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
